Phosphatidylinositol 3-kinase catalytic subunit delta isoform and Casein kinase 1 epsilon (PI3Kδ and CK1ε)

Phosphatidylinositol 3-kinase catalytic subunit delta isoform (PI3Kδ) is a lipid kinase primarily expressed in leukocytes, playing a central role in immune cell signal transduction, growth, and survival. Aberrant PI3Kδ activity contributes to cancer progression and immune disorders, making it a validated drug target for hematological malignancies and select autoimmune diseases. Casein kinase 1 epsilon (CK1ε) is a serine/threonine protein kinase involved in regulating various cellular processes, including circadian rhythm, Wnt signaling, and immune modulation. Certain drugs, like umbralisib, target both PI3Kδ and CK1ε to provide antitumor and immunomodulatory effects, with CK1ε inhibition improving regulatory T cell function and reducing immune toxicity seen with more selective PI3Kδ inhibitors. Both kinases are considered important targets for cancer and immunology therapeutics.

Other names

PI3K-deltap110δPIK3CDCKIεCSNK1ECasein kinase I epsilon

PI3Kδ inhibitors block ATP-binding, preventing PI3K-mediated signal transduction, particularly affecting lymphocyte survival and proliferation. CK1ε inhibitors prevent phosphorylation of protein substrates involved in signaling pathways, altering cell cycle regulation and immune modulation. Dual inhibition (umbralisib) targets both signaling pathways—PI3Kδ for immune cell suppression and CK1ε for improved T regulatory cell function, offering reduced immune-mediated toxicity.